---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-026914"
form_type: "8-K"
ticker: null
cik: "0001460602"
company_name: "Orgenesis Inc."
filed_at: "2026-06-02T21:26:42+00:00"
generated_at: "2026-06-02T21:28:33.269909+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Orgenesis shareholders approve 10x increase in authorized shares to 150M and convertible loan deal

## Summary
- Shareholders approved amendment to increase authorized common shares from 14,583,333 to 150,000,000.
- Vote: 5,153,345 for, 61,005 against, 1,201,381 abstentions on the amendment.
- Approved Convertible Loan Agreement with Theracell Laboratories IKE and Alpha Prosperity Fund SPC for potential share issuance.
- Ratified appointment of Kesselman & Kesselman (PwC) as auditor for FY 2025; votes: 6,400,038 for, 14,552 against.

## SEC filing metadata
- accession: 0001493152-26-026914
- form_type: 8-K
- cik: 0001460602
- company_name: Orgenesis Inc.
- filed_at: 2026-06-02T21:26:42+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460602/000149315226026914/0001493152-26-026914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460602/000149315226026914/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-026914
- JSON: https://secwatch.observer/filing/0001493152-26-026914.json
- Plain text: https://secwatch.observer/filing/0001493152-26-026914.txt

## Source-grounded claims
- claim_id: 4e40d062f497ec39a5b7ac04af76295d0b2feedd
  claim: Orgenesis Inc.: Increased authorized shares of common stock from 14,583,333 to 150,000,000 (effective 2026-06-02).
  evidence_excerpt: the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Articles of Incorporation, as amended (the “Charter”), to increase the total number of authorized shares of the Company’s common stock from 14,583,333 to 150,000,000. On June 2, 2026, the Company filed the Amendment with the Secretary of State of the State of Nevada with immediate effect.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460602/000149315226026914/0001493152-26-026914-index.htm
- claim_id: 9cc5b4582e74c98ceb02fae83f9521732c438235
  claim: Orgenesis Inc. shareholders approved Ratification of appointment of Kesselman & Kesselman C.P.A.s (member firm of PricewaterhouseCoopers) as independent registered public accounting firm for fiscal year ending December 31, 2025 at the 2026-05-27 meeting.
  evidence_excerpt: Proposal 3. Ratification of Auditors The approval of the ratification of the appointment of Kesselman & Kesselman C.P.A.s, a member firm of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2025: For Against Abstain 6,400,038 14,552 1,141
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460602/000149315226026914/0001493152-26-026914-index.htm
- claim_id: a6e3f6f1a40566713da8e5e961151118e49172a5
  claim: Orgenesis Inc. shareholders approved Amendment to Articles of Incorporation to increase authorized shares of common stock from 14,583,333 to 150,000,000 at the 2026-05-27 meeting.
  evidence_excerpt: Proposal 1. Amendment to Articles of Incorporation to Increase Authorized Shares of Common Stock The approval of a proposal to approve an amendment to the Company’s Articles of Incorporation, as amended, to increase the number of authorized shares of common stock from 14,583,333 to 150,000,000: For Against Abstain 5,153,345 61,005 1,201,381
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460602/000149315226026914/0001493152-26-026914-index.htm
- claim_id: dccdce18c8d6494e8b17eb5a665c4ac31f358c1e
  claim: Orgenesis Inc. shareholders approved Share Issuance Proposal - approval of Convertible Loan Agreement and potential issuance of shares at the 2026-05-27 meeting.
  evidence_excerpt: Proposal 2. Share Issuance Proposal The approval of the Convertible Loan Agreement, dated September 10, 2025, by and among Theracell Laboratories IKE, Orgenesis Inc., and Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P, and the potential issuance of shares of common stock of Orgenesis Inc. pursuant thereto: For Against Abstain 5,172,526 27,026 1,201,280
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460602/000149315226026914/0001493152-26-026914-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.